Adicet Bio, Inc.

ACET

Adicet Bio, Inc.

ACET

Insider Sentiment (TTM):

Last Purchase:2026-02-20Last Sale:2026-04-08Shares Purchased (TTM):5,074,751Shares Sold (TTM):72,939

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:6,224,573Shares Outstanding:10,744,621Institutional Ownership Pct.:57.93%

Earnings Market Reaction:

Filing Date:2026-08-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	33	36	39	29	35	28	56	105	224	160	160	183
Short Term Investments	-	-	-	-	-	-	-	97	-	-	-	-
Other Short Term Investments	85	101	120	74	90	122	120	-	-	-	0	-
Prepaid Expense And Other Assets Current	3	2	2	3	3	3	4	4	4	3	3	3
Assets Current	121	140	161	106	128	154	180	206	228	250	162	186
Goodwill	-	-	-	-	-	-	-	-	-	-	0	0
Finance Lease Right Of Use Asset	-	1	1	1	-	-	0	-	-	-	-	-
Restricted Cash Noncurrent	3	3	3	3	3	3	3	0	0	0	0	-
Property Plant And Equipment Net	14	15	17	18	20	21	23	24	24	25	27	28
Operating Lease Right Of Use Asset	10	10	11	12	13	13	14	15	16	17	17	18
Other Assets Noncurrent	0	0	0	0	0	0	0	1	1	1	1	1
Assets	148	169	192	140	163	191	220	246	269	293	207	233
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	4	3	5	4	3	4	5	3	2	3	3	4
Accrued Liabilities And Other Liabilities	12	12	14	11	11	9	11	14	13	12	13	13
Operating Lease Liability Current	3	3	3	3	3	3	3	3	3	3	3	3
Finance Lease Liability Current	-	0	0	0	-	-	0	-	-	-	-	-
Liabilities Current	18	18	22	19	17	16	19	19	18	17	19	20
Operating Lease Liability Noncurrent	9	10	11	12	12	13	14	15	16	17	18	19
Finance Lease Liability Noncurrent	-	1	1	1	-	-	0	-	-	-	-	-
Other Liabilities Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities	28	29	33	31	30	30	34	34	34	34	37	39
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	777	775	774	693	691	688	684	681	674	668	551	546
Retained Earnings Accumulated Deficit	-656	-635	-615	-584	-557	-526	-498	-469	-439	-409	-381	-351
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	-0	-0	0	0	-	-	0	-
Stockholders Equity	120	140	159	109	133	161	187	212	235	259	170	195
Liabilities And Stockholders Equity	148	169	192	140	163	191	220	246	269	293	207	233
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	150	150	150
Common Stock Shares Issued	9	10	10	5	5	5	5	5	5	5	3	3
Shares Outstanding	9	10	10	5	5	5	5	5	5	5	3	3
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-10.04%	11.52%	12.89%	-	-	-	-	-	-	-	-	-
2025	19.07%	3.81%	28.03%	4.80%	22.27%	29.55%	-6.09%	-24.64%	-23.55%	-0.71%	16.48%	32.24%
2024	1.50%	-19.55%	8.27%	13.85%	9.23%	-3.85%	-13.08%	-28.77%	-29.08%	-1.89%	-30.73%	-17.97%
2023	-	-	-	-5.71%	-34.76%	-40.00%	-7.52%	42.11%	90.23%	6.40%	-27.59%	-33.50%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	6.71	7.65	7.47	5.62	7.48	9.34	9.29	10.64	12.75	14.34	8.41	9.40
Quick Ratio	6.57	7.52	7.36	5.44	7.32	9.15	9.09	10.42	12.52	14.18	8.28	9.27
Working Capital	102.76M	121.77M	139.40M	87.55M	110.66M	137.12M	160.74M	186.92M	210.45M	232.89M	142.99M	166.12M
Leverage & Debt
Debt to Equity	0.23	0.21	0.21	0.29	0.22	0.18	0.18	0.16	0.14	0.13	0.22	0.20
Interest Coverage TTM	-1,280.35	-1,928.80	-3,392.06	-9,305.46	-63,086.00	-63,314.50	-31,903.75	-32,109.25	-36,886.50	-18,698.38	-6,081.52	-3,040.78
Debt Ratio	0.19	0.17	0.17	0.22	0.18	0.16	0.15	0.14	0.13	0.12	0.18	0.17
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-9.21	-10.13	-16.95	-20.20	-20.84	-20.61	-21.33	-20.76	-24.24	-28.29	-53.03	-53.25
Free Cash Flow Per Share TTM	-8.41	-8.80	-14.49	-13.41	-13.39	-17.09	-17.03	-16.35	-16.34	-19.28	-36.50	-37.18
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	-16.57%	-7.23%	-0.27%	-2.43%	-13.59%	-16.08%	-17.90%	-17.59%	19.22%	32.77%	104.41%	156.68%
EPS Growth (1Y)	-55.80%	-50.86%	-20.53%	-2.69%	-14.02%	-27.13%	-59.78%	-61.01%	-43.49%	-27.87%	95.09%	148.69%
Valuation Metrics
P/E TTM	-0.94	-0.67	-0.50	-0.64	-0.47	-0.59	-0.72	-1.11	-0.80	-1.33	-0.57	-0.41
P/B TTM	0.77	0.52	0.36	0.68	0.42	0.43	0.45	0.62	0.47	0.72	0.48	0.30
Market Cap	92.84M	73.17M	58.03M	73.78M	55.56M	68.76M	84.53M	130.82M	109.66M	185.82M	81.35M	58.88M
Enterprise Value	56.84M	37.91M	17.23M	42.74M	17.94M	40.63M	25.13M	25.34M	-114.40M	-61.77M	-78.36M	-124.37M
Calculated Values
Free Cash Flow TTM	-90.33M	-94.51M	-99.87M	-76.36M	-76.25M	-97.30M	-93.50M	-92.84M	-92.58M	-95.26M	-98.18M	-99.89M
Net Debt	-36.00M	-35.26M	-40.80M	-31.04M	-37.62M	-28.13M	-59.40M	-105.48M	-224.07M	-247.59M	-159.71M	-183.26M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-04-08Sale

Owner: Orbimed, Advisors Israel …

Title: -

Shares: 72,939

Price/Share: $6.40

Value: $466,809.60

Shares Owned: -

Relationship: TenPercentOwner

Ownership: Indirect

2026-02-20Purchase

Owner: Ra, Capital Healthcare Fu…

Title: -

Shares: 74,751

Price/Share: $7.27

Value: $543,439.77

Shares Owned: 1,182,624

Relationship: TenPercentOwner

Ownership: Indirect

2025-10-08Purchase

Owner: Orbimed, Advisors Llc, Or…

Title: -

Shares: 5,000,000

Price/Share: $1.00

Value: $5,000,000.00

Shares Owned: 9,026,359

Relationship: TenPercentOwner

Ownership: Indirect

2024-06-05Sale

Owner: Kauffman, Michael

Title: -

Shares: 5,900

Price/Share: $1.43

Value: $8,437.00

Shares Owned: 5,900

Relationship: Director

Ownership: Direct

2024-01-25Purchase

Owner: Gordon, Carl L

Title: -

Shares: 3,125,000

Price/Share: $2.40

Value: $7,500,000.00

Shares Owned: 7,526,359

Relationship: Director,TenPercentOwner

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-04-08	Orbimed, Advisors Israel …	TenPercentOwner	-	Indirect	Sale	72,939	6.40	$466,809.60	0	4
2026-02-20	Ra, Capital Healthcare Fu…	TenPercentOwner	-	Indirect	Purchase	74,751	7.27	$543,439.77	1,182,624	4
2025-10-08	Orbimed, Advisors Llc, Or…	TenPercentOwner	-	Indirect	Purchase	5,000,000	1.00	$5,000,000.00	9,026,359	4
2024-06-05	Kauffman, Michael	Director	-	Direct	Sale	5,900	1.43	$8,437.00	5,900	4
2024-01-25	Gordon, Carl L	Director,TenPercentOwner	-	Indirect	Purchase	3,125,000	2.40	$7,500,000.00	7,526,359	4
2024-01-25	Orbimed, Advisors Israel …	Director,TenPercentOwner	-	Indirect	Purchase	3,125,000	2.40	$7,500,000.00	7,526,359	4
2023-10-02	Schor, Chen	Director,Officer	President & CEO	Indirect	Purchase	5,500	1.33	$7,315.00	43,469	4
2023-09-29	Schor, Chen	Director,Officer	President & CEO	Direct	Sale	5,500	1.36	$7,480.00	176,969	4
2023-06-30	Dubin, Steve	Director	-	Direct	Purchase	5,000	2.40	$12,000.00	10,900	4
2023-06-27	Gordon, Carl L	Director,TenPercentOwner	-	Indirect	Purchase	875,000	2.09	$1,828,750.00	5,685,259	4
2023-06-27	Orbimed, Advisors Llc, Or…	Director,TenPercentOwner	-	Indirect	Purchase	875,000	2.09	$1,828,750.00	5,685,259	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

57.93%

Inst. Shares: 6,224,573

Shares Outstanding: 10,744,621

2025-12-31

93.68%

Inst. Shares: 6,455,658

Shares Outstanding: 6,891,336

2025-09-30

Inst. Shares: 48,973,367

Shares Outstanding: 5,692,904

2025-06-30

Inst. Shares: 49,343,925

Shares Outstanding: 5,692,844

2025-03-31

Inst. Shares: 53,780,755

Shares Outstanding: 5,691,965

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	6,224,573	10,744,621	57.93%
2025-12-31	6,455,658	6,891,336	93.68%
2025-09-30	48,973,367	5,692,904	-
2025-06-30	49,343,925	5,692,844	-
2025-03-31	53,780,755	5,691,965	-
2024-12-31	55,484,076	5,491,652	-
2024-09-30	54,720,699	5,677,893	-
2024-06-30	62,771,689	5,664,503	-
2024-03-31	73,208,682	4,941,978	-
2023-12-31	29,215,157	2,690,150	-
2023-09-30	33,852,947	2,686,290	-
2023-06-30	36,118,250	2,684,815	-
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Adicet Bio, Inc. (ACET) — SEC Financial Statements & Analysis

Adicet Bio, Inc. (ACET) is a pharmaceutical preparations company, incorporated in DE. Adicet Bio, Inc. trades on Nasdaq as: ACET. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Adicet Bio, Inc. reported a Debt-to-Equity ratio of 0.23x, a Price-to-Book (P/B) ratio of 0.77x (TTM), at a market cap of $92.84M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.23x
P/B TTM: 0.77x
Market Cap: $92.84M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Adicet Bio, Inc. in?

Adicet Bio, Inc. (ACET) operates in the Pharmaceutical Preparations industry.

What is ACET's market cap?

Adicet Bio, Inc. (ACET) has a market capitalization of $92.84M as of 2026-06-30.

What exchange does ACET trade on?

Adicet Bio, Inc. (ACET) trades on the Nasdaq.

Where is Adicet Bio, Inc. incorporated?

Adicet Bio, Inc. is incorporated in DE.

Adicet Bio, Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

Adicet Bio, Inc. (ACET) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

Adicet Bio, Inc. (ACET) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.